​

vTv Therapeutics (VTVT) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

VTVT Stock Forecast

vTv Therapeutics (VTVT) stock forecast, based on 13 Wall Street analysts, predicts a 12-month average price target of $51.33, with a high of $58.00 and a low of $47.00. This represents a 51.59% increase from the last price of $33.86.

$10 $20 $30 $40 $50 $60 High: $58 Avg: $51.33 Low: $47 Last Closed Price: $33.86

VTVT Stock Rating

vTv Therapeutics stock's rating consensus is Hold, based on 13 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 6 Buy (46.15%), 7 Hold (53.85%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Hold
Total 13 0 7 6 Strong Sell Sell Hold Buy Strong Buy

VTVT Price Target Upside V Benchmarks

TypeNameUpside
StockvTv Therapeutics51.59%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts233
Avg Price Target$53.50$51.33$51.33
Last Closing Price$33.86$33.86$33.86
Upside/Downside58.00%51.59%51.59%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 26-21--3
Dec, 25-21--3
Nov, 2511---2
Oct, 2511---2
Sep, 2511---2
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jan 27, 2026Kambiz YazdiBTIG$49.00$33.8644.71%44.71%
Jan 22, 2026Roth Capital$58.00$33.5472.93%71.29%
Dec 19, 2025H.C. Wainwright$47.00$36.3029.48%38.81%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jan 27, 2026BTIGBuyBuyhold
Jan 22, 2026Roth CapitalBuyinitialise
Jan 05, 2026Cowen & Co.Buyinitialise
Dec 19, 2025H.C. WainwrightBuyBuyhold
Feb 18, 2022Cantor FitzgeraldOverweightinitialise

Financial Forecast

EPS Forecast

$-35 $-28 $-21 $-14 $-7 $0 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27
Reported$-11.32$-13.06$-9.71$-3.20---
Avg Forecast$-6.80$-10.80$-31.20$-3.65$-4.85$-5.10$-5.20
High Forecast$-6.80$-10.80$-31.20$-3.65$-4.85$-5.10$-5.20
Low Forecast$-6.80$-10.80$-31.20$-3.65$-4.85$-5.10$-5.20
Surprise %66.47%20.93%-68.88%-12.33%---

Revenue Forecast

Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27
Reported$4.00M$2.02M-$1.02M---
Avg Forecast$4.33M$2.01M-$1.00M---
High Forecast$4.33M$2.01M-$1.00M---
Low Forecast$4.33M$2.01M-$1.00M---
Surprise %-7.55%0.60%-1.70%---

Net Income Forecast

$-70M $-56M $-42M $-28M $-14M $0 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27
Reported$-17.73M$-25.07M$-20.25M$-18.46M---
Avg Forecast$-14.18M$-6.38M$-65.05M$-7.61M$-10.11M$-10.63M$-10.84M
High Forecast$-14.18M$-4.19M$-65.05M$-7.61M$-10.11M$-10.63M$-10.84M
Low Forecast$-14.18M$-8.56M$-65.05M$-7.61M$-10.11M$-10.63M$-10.84M
Surprise %25.06%293.28%-68.87%142.60%---

VTVT Forecast FAQ

Is vTv Therapeutics stock a buy?

vTv Therapeutics stock has a consensus rating of Hold, based on 13 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 6 Buy, 7 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that vTv Therapeutics is a neutral investment for most analysts.

What is vTv Therapeutics's price target?

vTv Therapeutics's price target, set by 13 Wall Street analysts, averages $51.33 over the next 12 months. The price target range spans from $47 at the low end to $58 at the high end, suggesting a potential 51.59% change from the previous closing price of $33.86.

How does vTv Therapeutics stock forecast compare to its benchmarks?

vTv Therapeutics's stock forecast shows a 51.59% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for vTv Therapeutics over the past three months?

  • January 2026: 0% Strong Buy, 66.67% Buy, 33.33% Hold, 0% Sell, 0% Strong Sell.
  • December 2025: 0% Strong Buy, 66.67% Buy, 33.33% Hold, 0% Sell, 0% Strong Sell.
  • November 2025: 50.00% Strong Buy, 50.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is vTv Therapeutics’s EPS forecast?

vTv Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-4.85, marking a 51.56% increase from the reported $-3.2 in 2024. Estimates for the following years are $-5.1 in 2026, and $-5.2 in 2027.

What is vTv Therapeutics’s revenue forecast?

vTv Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $0, reflecting a -100.00% decrease from the reported $1.02M in 2024. The forecast for 2026 is $0, and $0 for 2027.

What is vTv Therapeutics’s net income forecast?

vTv Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-10.112M, representing a -45.23% decrease from the reported $-18.462M in 2024. Projections indicate $-10.633M in 2026, and $-10.842M in 2027.